IP Library Granted Patent US 8,076,449
Granted Patent B2
US 8,076,449 · App. 11/578,142 · Granted Dec 13, 2011

Therapeutic agents of colivelin for neurodegenerative diseases

Assignees: Tomohiro Chiba; Massaaki Matsuoka; Kenzo Terashita; Sadakazu Also; Tomo Nishimoto
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,076,449
App. No.
11/578,142
Granted
Dec 13, 2011
Kind
B2
Abstract

The present invention relates to a pharmaceutical composition for the treatment and/or prevention of a neurodegenerative disease, comprising the following polypeptide shown in any of (a) to (c): (a) a polypeptide comprising the amino acid sequence represented by Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala-Pro-Ala-Gly-Ala-Ser-Arg-Leu-Leu-Leu-Leu-Thr-Gly-Glu-Ile-Asp-Leu-Pro (SEQ ID NO: 1); (b) a polypeptide comprising an amino acid sequence having a deletion, substitution, insertion, and/or addition of one or several amino acids in the amino acid sequence consisting of Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala-Pro-Ala-Gly-Ala-Ser-Arg-Leu-Leu-Leu-Leu-Thr-Gly-Glu-Ile-Asp-Leu-Pro (SEQ ID NO: 1), and having an activity that inhibits neuronal cell death associated with neurodegenerative disease; and (c) a modified polypeptide from the polypeptide (a) or (b), or a pharmaceutically acceptable salt thereof, as an effective ingredient.

Claims (7)

1. A pharmaceutical composition for neuroprotection from neuronal cell death in a neurodegenerative disease selected from amyotrophic lateral sclerosis (ALS) or Alzheimer's disease, comprising: (a) an isolated polypeptide comprising the amino acid sequence as defined by Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala-Pro-Ala-Gly-Ala-Ser-Arg-Leu-Leu-Leu-Leu-Thr-Gly-Glu-Ile-Asp-Leu-Pro (SEQ ID NO: 1); or (b) a pharmaceutically acceptable salt of the polypeptide of (a).

2. The pharmaceutical composition according to claim 1 , wherein the isolated polypeptide is a dimer.

3. An isolated polypeptide comprising the amino acid sequence as defined by Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala-Pro-Ala-Gly-Ala-Ser-Arg-Leu-Leu-Leu-Leu-Thr-Gly-Glu-Ile-Asp-Leu-Pro (SEQ ID NO: 1), or a salt thereof.

4. The isolated polypeptide according to claim 3 , wherein the polypeptide is a dimer.

5. The pharmaceutical composition according to claim 1 , comprising approximately 100 fM or a higher concentration of the polypeptide (a).

6. The pharmaceutical composition according to claim 1 , comprising the isolated polypeptide consisting of the amino acid sequence as defined by Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala-Pro-Ala-Gly-Ala-Ser-Arg-Leu-Leu-Leu-Leu-Thr-Gly-Glu-Ile-Asp-Leu-Pro (SEQ ID NO: 1).

7. The isolated polypeptide according to claim 3 , wherein the isolated polypeptide consists of the amino acid sequence as defined by Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala-Pro-Ala-Gly-Ala-Ser-Arg-Leu-Leu-Leu-Leu-Thr-Gly-Glu-Ile-Asp-Leu-Pro (SEQ ID NO: 1).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 13, 2008
From: CHIBA, TOMOHIRO; MATSUOKA, MASAAKI; TERASHITA, KENZO; AISO, SADAKAZU; NISHIMOTO, TOMO
To: TOMOHIRO CHIBA; MASAAKI MATSUOKA; KENZO TERASHITA; SADAKAZU AISO; TOMO NISHIMOTO
Reel/Frame 020648/0896 →
Continuity (2)
Provisional Application 60560254 · Apr 8, 2004
Related Publication 20080227699A1 · Sep 18, 2008